Apalutamide/AAP Improves Outcomes Without Negative HRQOL Impact in Prostate Cancer
January 26th 2024Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.